SAN DIEGO, CA--(Marketwire - Apr 28, 2011) - Therapeutic Solutions International, Inc. (OTCQB: TSOI) (PINKSHEETS: TSOI), the only manufacturer of the chairside NTI Tension Suppression System that has helped countless patients prevent debilitating migraine and tension headache pain, announced today the signing of a sales and distribution agreement with S4S (UK) Limited, a dental laboratory and supply company, headquartered in Woodseats, Sheffield, United Kingdom.

"We are very pleased to sign this sales agreement with S4S Dental," stated Tim Dixon, President of TSI. "As we continue in our efforts to expand our market and bring this patented technology to markets worldwide, the availability of the NTI Tension Suppression System will allow dentists throughout the United Kingdom (England, Scotland, Northern Ireland & Wales) & the Republic of Ireland the ability to provide this unique chairside dental product to their patients."

"S4S is proud to represent Therapeutic Solutions International, Inc. in the UK," said Neil Bullement, Commercial Director of S4S. "The recently signed distributor agreement means that we can continue to offer the excellent range of NTI-tss products to our clients. Purchasing directly from the manufacturer will enable us to significantly increase sales by reducing the end price. We look forward to a long and prosperous collaboration with Therapeutic Solutions."

About S4S (UK) Limited

Solutions 4 Snoring is a UK company formed out of the need to address a growing problem for a large number of the population. Its founders have vast experience in the clinical and dental sector. S4S's website is

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International, Inc. is a company whose business plan is focused on the development, production and marketing of cost effective technologies and therapeutic modalities for the treatment and prevention of common neurologic, sleep and temporomandibular disorders. TSI has several important websites to disseminate information and market their products. Our clinical research site for the NTI is and our e-commerce portal is located at Our patient education site located at, and our corporate website for TSI is

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at